Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering trans

Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported,

Kyverna Therapeutics, Inc. (NASDAQ: KYTX - Get Free Report) has received an average rating of "Moder

Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS

Kyverna Therapeutics reports positive one-year clinical trial data for miv-cel in stiff person syndr

Sustained clinical benefit and reversal of disability through one year support the potential to be t

Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long

Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conferenc

EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a

Kyverna Therapeutics, Inc. remains a compelling Buy as it advances mivocabtagene autoleucel for auto

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.63) per share which beat the ana

FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSP

Kyverna Therapeutics remains a 'Strong Buy' as miv-cel advances in SPS, gMG, and refractory RA with

Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing

EMERYVILLE, Calif., and WALTHAM, Mass.

Shares of Kyverna Therapeutics (NASDAQ:KYTX) are down almost 13% in Friday afternoon trading, changi

Kyverna Therapeutics is positioned to pioneer the autoimmune CAR T space, leveraging miv-cel as a po

EMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a l

A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct f

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX)

Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response

Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response

Veteran biopharma leader joins to help lead Kyverna's next phase of commercial growth Veteran biopha

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) w

EMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a la

JP Morgan analyst Brian Cheng maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.66) per share which beat the ana

Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndr

EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a la

Kyverna Therapeutics (NASDAQ: KYTX) highlighted new clinical data for its CD19-directed autologous C

Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial

RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Ph

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty i